Mitophagy Induction as Neuroprotective Strategy in Sporadic Parkinson's Disease
🧪 Overview
PINK1/PARKIN-mediated mitophagy is impaired in sporadic PD due to upstream mitochondrial stress. Enhancing parkin translocation or inhibiting USP30 (deubiquitinase opposing mitophagy) can restore clearance of damaged mitochondria. This hypothesis extrapolates from familial PD (PINK1/PARKIN mutations) to sporadic disease without direct evidence of shared mechanism. USP30 inhibitors showed promising preclinical neuroprotection but have not translated to clinical success. The fundamental problem is the Familial-to-Sporadic Gap—assuming identical mechanisms in genetic vs. idiopathic PD lacks validation. Multiple compensatory mitophagy pathways (FUNDC1, BNIP3) may limit therapeutic potential. The hypothesis received the most severe confidence reduction from the Skeptic (0.62), reflecting failed clinical translation despite strong preclinical data.
🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["USP30<br/>Deubiquitinase"]
B["Mitochondrial<br/>TOMM20 Receptor"]
C["Mitophagy Receptor<br/>Regulation"]
D["Mitochondrial<br/>Quality Control"]
E["Parkin-mediated<br/>Mitophagy"]
F["Dopaminergic<br/>Neuron Survival"]
G["LRRK2-associated<br/>Mitophagy Defect"]
A --> B
B --> C
C --> D
D --> F
E --> F
G --> D
G --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
style G fill:#6a1b9a,stroke:#ce93d8,color:#ce93d8⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — USP30
No curated PDB or AlphaFold mapping for USP30 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for USP30 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for USP30.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF we administer a selective USP30 inhibitor (e.g., DC67150 or probe compound) to iPSC-derived dopaminergic neurons from sporadic PD patients AND compare to age-matched controls, THEN we will observe | Mitophagic flux will increase by >40% in sporadic PD iPSC-derived neurons treated with USP30 inhibitor compared to vehicle control, with statistical significanc | — no observation — | pending | 0.35 |
| IF we genetically knockdown FUNDC1 or BNIP3 (alternative mitophagy receptors) using CRISPR/Cas9 in conjunction with USP30 inhibitor treatment in sporadic PD patient-derived neurons, THEN neuroprotecti | Neurite length and OCR (oxygen consumption rate) will decrease by >50% when FUNDC1 or BNIP3 is knocked down alongside USP30 inhibition, returning toward baselin | — no observation — | pending | 0.28 |
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |